Merck Company Stock Price To Earnings To Growth
| 0QAH Stock | USD 98.40 0.20 0.20% |
Merck Company fundamentals help investors to digest information that contributes to Merck's financial success or failures. It also enables traders to predict the movement of Merck Stock. The fundamental analysis module provides a way to measure Merck's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merck stock.
Merck | Price To Earnings To Growth |
Merck Company Company Price To Earnings To Growth Analysis
Merck's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Merck Price To Earnings To Growth | 0.07 X |
Most of Merck's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merck Company is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Merck Company has a Price To Earnings To Growth of 0.0695 times. This is 90.21% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earnings to growth for all United Kingdom stocks is 98.58% higher than that of the company.
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Merck Fundamentals
| Return On Equity | 0.0761 | ||||
| Return On Asset | 0.0512 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 272.15 B | ||||
| Shares Outstanding | 2.54 B | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 77.64 % | ||||
| Price To Book | 5.60 X | ||||
| Price To Sales | 4.29 X | ||||
| Revenue | 60.12 B | ||||
| Gross Profit | 42.7 B | ||||
| EBITDA | 12.33 B | ||||
| Net Income | 365 M | ||||
| Cash And Equivalents | 7 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 1.37 B | ||||
| Debt To Equity | 1.16 % | ||||
| Book Value Per Share | 15.24 X | ||||
| Cash Flow From Operations | 13.01 B | ||||
| Earnings Per Share | 1.22 X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Number Of Employees | 67 K | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 250.2 B | ||||
| Total Asset | 106.67 B | ||||
| Retained Earnings | 53.9 B | ||||
| Working Capital | 6.47 B | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 3.07 % | ||||
| Net Asset | 106.67 B | ||||
| Last Dividend Paid | 2.84 |
About Merck Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merck Company's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merck using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merck Company based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.